Anti-Aging Stack

A 2025 paper changed the conversation around this peptide. Al-Dulaimi and colleagues replicated epithalon's telomere elongation effect in human cell lines (PMID 40908429), confirming telomerase upregulation independent of Khavinson's lab for the first time. Epithalon (epitalon, molecular weight 390.35 Da) is a synthetic tetrapeptide modeled after epithalamin, a pineal gland extract. It activates telomerase, the enzyme that adds TTAGGG repeats to chromosome ends. Short telomeres push cells into senescence or death. Restoring telomerase activity, at least in theory, reverses that clock. The practical picture is more complicated. Every published human observation comes from Khavinson's own unblinded cohorts in elderly Russian populations during the 1990s and 2000s. No randomized controlled trial exists. A 2025 IJMS review (PMID 40141547) noted explicitly that safety information on this peptide is missing. Community use tells a different story. Hundreds of users across peptide forums run 10-day cycles twice per year and report rapid sleep improvement, typically by day 3 to 5. That effect operates through pineal melatonin normalization, a faster and better-understood mechanism than telomere extension. Deeper sleep, fewer awakenings, and improved morning energy are the most reproducible outcomes. The telomere claim itself is taken largely on faith since no practical at-home marker exists; telomere testing before and after multiple cycles is the only objective route, and single-measurement variability is large. At roughly $33 to $50 per 10-day cycle, epithalon is one of the cheapest peptides in the longevity space. Epithalon was on the FDA Category 2 list until April 15, 2026. PCAC review begins July 2026. All current supply is research-grade.

Four thousand genes. That's the number GHK-Cu flips toward repair when it binds to human cells, according to gene expression profiling by Pickart's group (PMID 25789553, 26236730). The GHK-Cu peptide (glycyl-L-histidyl-L-lysine copper(II), also written GHK:Cu or copper tripeptide-1) is a naturally occurring copper peptide found in human plasma, saliva, and urine. Plasma levels sit around 200 ng/mL at age 20 and drop to roughly 80 ng/mL by age 60. The mechanism is broad. GHK-Cu upregulates collagen I, III, and V synthesis, boosts elastin and decorin production, and recruits immune and endothelial cells to damaged tissue. The copper ion itself is required for enzymatic processes in wound remodeling. In 2024, Bian and colleagues confirmed anti-fibrotic activity in a silicosis lung model with human biomarker data (PMID 38879894), expanding the peptide's research footprint beyond skin. In practice, two routes dominate. Topical formulations (1 to 3% concentration) have cosmetic safety data going back decades; small clinical trials (n = 41 to 71) showed improved skin density and fine line reduction. Injectable use (0.5 to 2 mg/day subcutaneous) has no published dose-finding trial in humans but has one of the largest community evidence bases of any anti-aging peptide. Reports across r/Peptides, r/Biohackers, and practitioner networks describe improved skin firmness by weeks four to six; sentiment runs at 4.2 out of 5. The honest limitation: all mechanistic data is in vitro or murine. Pro-angiogenic activity flagged by the NCI raises an unresolved theoretical oncology concern. GHK-Cu is classified as research-only and is not FDA-approved for any indication.

A 398% spike in plasma levels after one six-hour drip. That single data point from a 2019 pilot study (PMID 31572171) turned NAD+ (Nicotinamide Adenine Dinucleotide, CAS 53-84-9) from a biochemistry footnote into one of the most discussed molecules in longevity circles. NAD+ sits at the center of cellular energy metabolism. It shuttles electrons through glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation to produce ATP. It also feeds three enzyme families that control aging: sirtuins (SIRT1 through SIRT7), PARPs for DNA repair, and CD38, an ectoenzyme whose activity rises with age and is now considered a primary driver of NAD+ decline. Between ages 40 and 60, cellular NAD+ drops roughly 50%. The practical question is whether restoring those levels from the outside actually changes outcomes. For addiction recovery, the answer looks promising. The BR+NAD protocol (500 to 1,500 mg/day IV over 10 days) reduced craving scores from 5.9 to 0.22 in 50 substance use disorder patients (PMID 36118157). For general wellness and anti-aging, the community runs ahead of the science. Hundreds of threads across r/Nootropics, r/longevity, and r/Peptides consistently report improved energy, reduced brain fog, and better exercise recovery with subcutaneous dosing at 100 to 250 mg twice weekly. A 2024 systematic review (PMID 37971292) confirmed safety across clinical conditions but called the efficacy evidence "heterogeneous." Science has not refuted the wellness case; data simply lags community adoption.